Fulgent Genetics' 15-Min Chart Experiences Bollinger Bands Narrowing, Bearish Marubozu Pattern
ByAinvest
Tuesday, Apr 22, 2025 2:04 pm ET1min read
FLGT--
The company's non-GAAP income for 2024 was $15 million, or $0.49 per share, indicating a more optimistic financial picture when adjusted for non-recurring items. The fourth quarter GAAP gross margin was 41.8%, while the non-GAAP gross margin was 44.2%. The company also reported an adjusted EBITDA of $774,000 and non-GAAP income of $1.2 million, or $0.04 per share.
FLGT's financials were bolstered by strategic advancements, including the initiation of Phase 2 clinical trials for FID-007 and the clearance of an investigational new drug application for FID-022. The company also launched new products, such as the exome and genome RISE, which could potentially increase diagnostic yield by as much as 30%. Furthermore, FLGT formed a new partnership with Foundation Medicine, which is expected to enhance their precision diagnostics offerings [1].
Looking ahead, FLGT expects core revenue to reach approximately $310 million in 2025, representing a 10% year-over-year growth. The company anticipates a non-GAAP gross margin of slightly exceeding 40% and a non-GAAP operating margin of approximately minus 15%. However, FLGT expects a GAAP EPS loss of approximately $1.95 per share and a non-GAAP loss of $0.65 per share. The company also expects to maintain a cash position of approximately $780 million in 2025 [1].
Analyzing the stock's technical indicators, a narrowing of the Bollinger Bands and a bearish Marubozu at 14:00 on 04/22/2025 suggest a decline in stock price volatility. This indicates that sellers are currently in control of the market, and bearish momentum is likely to persist [2].
References:
[1] https://finance.yahoo.com/news/fulgent-genetics-inc-flgt-q4-203712496.html
[2] Chart data for Fulgent Genetics Inc. (FLGT)
Based on the 15-minute chart for Fulgent Genetics, a narrowing of the Bollinger Bands and a bearish Marubozu at 14:00 on 04/22/2025 indicates a decline in stock price volatility, suggesting that sellers are currently in control of the market. This bearish momentum is likely to persist.
Fulgent Genetics Inc. (FLGT) reported its fourth quarter (Q4) 2024 earnings on February 28, 2025, revealing a 7% year-over-year growth in core revenue to $281.2 million. This marks a significant increase from the previous year's $280 million guidance. The company's fourth quarter revenue stood at $76.2 million, up from $70.5 million in Q4 2023. Despite the positive revenue growth, FLGT reported a GAAP loss of $42.7 million for 2024, translating to a loss of $1.41 per share [1].The company's non-GAAP income for 2024 was $15 million, or $0.49 per share, indicating a more optimistic financial picture when adjusted for non-recurring items. The fourth quarter GAAP gross margin was 41.8%, while the non-GAAP gross margin was 44.2%. The company also reported an adjusted EBITDA of $774,000 and non-GAAP income of $1.2 million, or $0.04 per share.
FLGT's financials were bolstered by strategic advancements, including the initiation of Phase 2 clinical trials for FID-007 and the clearance of an investigational new drug application for FID-022. The company also launched new products, such as the exome and genome RISE, which could potentially increase diagnostic yield by as much as 30%. Furthermore, FLGT formed a new partnership with Foundation Medicine, which is expected to enhance their precision diagnostics offerings [1].
Looking ahead, FLGT expects core revenue to reach approximately $310 million in 2025, representing a 10% year-over-year growth. The company anticipates a non-GAAP gross margin of slightly exceeding 40% and a non-GAAP operating margin of approximately minus 15%. However, FLGT expects a GAAP EPS loss of approximately $1.95 per share and a non-GAAP loss of $0.65 per share. The company also expects to maintain a cash position of approximately $780 million in 2025 [1].
Analyzing the stock's technical indicators, a narrowing of the Bollinger Bands and a bearish Marubozu at 14:00 on 04/22/2025 suggest a decline in stock price volatility. This indicates that sellers are currently in control of the market, and bearish momentum is likely to persist [2].
References:
[1] https://finance.yahoo.com/news/fulgent-genetics-inc-flgt-q4-203712496.html
[2] Chart data for Fulgent Genetics Inc. (FLGT)
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet